QM · rank #17 · 2026-10-21
SNT
GPW · PLN · $751M (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +45.61% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +217.6% |
| Profit margin Net profit margin, trailing 12 months. | +44.8% |
| Market cap (USD) Size filter: > $300M required (USD-equivalent). | $751M |
| Anchor (recent) Close on 2026-09-21 | $351.40 |
| Anchor (far) Close on 2025-09-19 | $241.33 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Synektik S.A. is a CEE medical technology company distributing and servicing Intuitive Surgical da Vinci robotic-surgery systems alongside recurring consumables, medical devices, and radiopharmaceuticals.
Rationale
Exceptional profit margins (44.8%), high ROE, and 52% 9M revenue growth driven by a 35% expansion in da Vinci procedures validate the quality-momentum signal, backed by an exclusive distribution contract extended through December 2031.
Material risks
- 1Public-healthcare tender lumpiness and delayed procurement cycles across regional hospitals, evidenced by the contraction in committed backlog to PLN 43.3 million from PLN 75.9 million a year earlier.
- 2Heavy supplier-concentration risk on Intuitive Surgical and longer-term threat of technology-path displacement by rival robotic platforms such as Medtronic Hugo or CMR Versius.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.